Abivax clinical trials we track

Check company identity source

Phase 3 3 trials

TrialDrugs studiedStatusPrimary completion
ABTECT - MaintenanceNCT05535946ABX464Active not recruiting2026-04-28Actual
ABTECT-1 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -1NCT05507203ABX464Completed2025-06-24Actual
ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2NCT05507216ABX464Completed2025-06-24Actual

ABTECT - Maintenance

Active not recruitingPrimary completion: 2026-04-28 · Actual
Trial details
Registry ID
NCT05535946
Drugs studied
ABX464

Phase 2 / 3 1 trial

TrialDrugs studiedStatusPrimary completion
ABX464 in Treating Inflammation and Preventing Acute Respiratory Failure in Patients With COVID-19NCT04393038ABX464Terminated2021-03-05Actual

Phase 2 8 trials

Phase 1 / 2 1 trial

TrialDrugs studiedStatusPrimary completion
ABX196 in Combination With Nivolumab in Patients With Hepatocellular CarcinomaNCT03897543ABX196Completed2022-04-14Actual

Drugs in these trials

Names as written in the registry records.

Latest recorded trial changes

Filters
Clear filters

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8. After: Measure: Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Proportion of subjects who achieve clinical remission per Modified Mayo Score at week 8. After: Measure: Proportion of Subjects Who Achieve Clinical Remission Per Modified Mayo Score at Week 8.

Check registry source
ABTECT - Maintenance

NCT05535946 · Abivax S.A.

· 2 fields changed

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Apr 2026. After: 28 Apr 2026.

Check registry source

· 1 field changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Rate of patients with no invasive or non-invasive mechanical ventilation (IMV and NIV, respectively), but excluding simple nasal/mask oxygen supplementation, and who are alive. After: Measure: Rate of Responders: i.e. Rate of Patients Who do Not Require Use of High-flow Oxygen Invasive or Non-invasive Mechanical Ventilation (IMV and NIV, Respectively) Within 28 Days and Who Are Alive at the End of the 28 Days Period..

Check registry source